Search Results - autoimmunity

4 Results Sort By:
Transcription Factors in B cells as Targets for Therapeutic Modulation in SLE
This technology introduces a novel therapeutic approach for systemic lupus erythematosus (SLE) by modulating specific transcription factors in B cells to restore immune tolerance and prevent autoimmunity. Background: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the production of harmful autoantibodies from self-reactive...
Published: 6/29/2026   |   Updated: 6/24/2026   |   Inventor(s): Christopher Roman, Abhimanyu Amarnani
Keywords(s): autoimmune disease, autoimmunity, drug mechanism, gene expression analysis, immune disease, lupus, molecular pharmacology, targeted therapeutic delivery, Technologies
Category(s): Campus > SUNY Downstate Health Sciences University, Technology Classifications > Therapeutics and Vaccines
Mice, Organs, and Mouse Alleles Carrying Germline and Conditional Deletions of the Zbtb7b Gene
Summary: The NCI seeks parties interested in licensing this mouse model, including the mice, organs, tissues, and other derivatives from mice carrying deletions of the Zbtb7b gene. Description: The Zbtb7b gene encodes the zinc finger transcription factor ThPOK (also known as cKrox) that promotes CD4 lineage differentiation in immature T cells. CD4+...
Published: 4/23/2026   |   Updated: 8/2/2023   |   Inventor(s):  
Keywords(s): Autoimmunity, Bosselut, CANCER, CD4, cKrox, Helper T Cell, Infection, LYMPHOCYTE, Memory T Cell, Oncology, ThPOK, transgenic mice, Zbtb7b, Zinc Finger Transcription Factor
Category(s): TherapeuticArea > Infectious Disease, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Research Materials, TherapeuticArea > Immunology
IL7Rα-Specific Antibody for Treating Acute Lymphoblastic Leukemia (ALL)
Abstract: Acute lymphoblastic leukemia (ALL) is the most common cancer in children with approximately 3,250 new cases occurring per year in the United States. About 20% of cases are refractory to current treatment protocols and there is a desperate need for targeted therapies that do not result in adverse side effects such as cognitive impairment.  The...
Published: 4/23/2025   |   Updated: 8/2/2023   |   Inventor(s): Scott Durum, Julie Hixon, Wenqing Li, Scotch Walsh, Lila Kashi
Keywords(s): Acute lymphoblastic leukemia (ALL), ANTIBODY, Antibody-Dependent Cellular Cytotoxicity (ADCC), Autoimmunity, CANCER, DIABETES, Durum, Interleukin-7 receptor-α (IL-7Rα), Multiple sclerosis, personalized medicine, Targeted therapy, THERAPY, TRANSPLANTATION
Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Collaboration
Muramyl Dipeptide as a Therapeutic Agent for Inflammation
The nucleotide-binding oligomerization domain 2 (NOD2) protein plays a key role in innate immunity as a sensor of muramyl dipeptide (MDP), a breakdown product of bacterial peptidoglycan. Bacterial peptidoglycan promotes the innate immune response through the activation of Toll-like receptor 2 (TLR2), which ultimately provokes inflammation. Activation...
Published: 3/26/2026   |   Updated: 12/6/2022   |   Inventor(s): Warren Strober
Keywords(s): Autoimmune, AUTOIMMUNE DISEASE, Autoimmune disorder, Autoimmunity, BBXXXX, BCXXXX, BOWEL, Crohn disease; Inflammatory bowel disease 1, Crohn's disease, Dipeptide, IB3XXX, IBD, IBXXXX, IL-12, Inflammation, INFLAMMATORY, inflammatory bowel disease, Inflammatory bowel disease 1, inflammatory disease, INTERLEUKIN, INTERLEUKIN-12, IRF4, IXXXXX, MDP, Muramyl, NOD2, peptidoglycan, TLR, TLR2, Toll-like, Toll-like receptors, Ulcerative Colitis
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Immunology, Application > Research Materials, Application > Diagnostics